Alnylam stock drops 28% after Q2 miss, but analysts see 89% upside potential

Alnylam Pharmaceuticals' stock fell 28.3% after missing Q2 2026 earnings and revenue estimates, with adjusted earnings of $1.84 per share and $1.29 billion in revenue. Despite lowering sales guidance for its TTR products, the company reported strong 67% year-over-year revenue growth and over $1 billion in sales for its lead drug, Amvuttra. Analyst firm H.C. Wainwright set a new price target of $455, implying an 88.97% potential upside, reflecting confidence in Alnylam's drug pipeline and future growth. The company also raised its outlook for collaboration and royalty revenue, which may support financial stability moving forward.